ALX Oncology Holdings Inc
ALXO1.450USD
+0.040+2.84%
Close 12/19, 16:00（ET）Quotes delayed by 15 min
77.69MMarket Cap
LossP/E TTM
More Details of ALX Oncology Holdings Inc Company
ALX Oncology Holdings Inc. is a clinical-stage biotechnology company advancing a pipeline of therapies designed to treat cancer and extend patients’ lives. The Company's lead product candidate, evorpacept, is a CD47 blocking therapeutic that combines a high-affinity CD47 binding domain with an inactivated, proprietary Fc domain. It is engaged in focusing on combining evorpacept with anti-cancer antibodies, antibody drug conjugate (ADCs), and PD-1/PD-L1 immune checkpoint inhibitors. Evorpacept is being evaluated across multiple ongoing clinical trials in a range of cancer indications. Its second product candidate is ALX2004, an epidermal growth factor receptor (EGFR)-targeted ADC. ALX2004 comprises an affinity-tuned EGFR antibody backbone engineered for optimal activity as an ADC, a proprietary topoisomerase I inhibitor payload with enhanced bystander effect, and a linker with enhanced stability.
ALX Oncology Holdings Inc Info
Ticker SymbolALXO
Company nameALX Oncology Holdings Inc
IPO dateJul 17, 2020
CEOLettmann (Jason)
Number of employees80
Security typeOrdinary Share
Fiscal year-endJul 17
Address323 Allerton Avenue
CitySOUTH SAN FRANCISCO
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code94080
Phone16504667125
Websitehttps://alxoncology.com/
Ticker SymbolALXO
IPO dateJul 17, 2020
CEOLettmann (Jason)
Company Executives of ALX Oncology Holdings Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Jason Lettmann
Mr. Jason Lettmann
Chief Executive Officer, Director
Chief Executive Officer, Director
215.12K
+75.05%
Dr. Corey S. Goodman
Dr. Corey S. Goodman
Executive Chairman of the Board
Executive Chairman of the Board
167.37K
--
Mr. Harish Shantharam
Mr. Harish Shantharam
Chief Financial Officer
Chief Financial Officer
75.00K
--
Ms. Shelly Pinto
Ms. Shelly Pinto
Senior Vice President - Finance, Chief Accounting Officer
Senior Vice President - Finance, Chief Accounting Officer
39.07K
-1.54%
Ms. Rekha Hemrajani
Ms. Rekha Hemrajani
Independent Director
Independent Director
33.00K
+1000.00%
Dr. Daniel J. Curran, M.D.
Dr. Daniel J. Curran, M.D.
Independent Director
Independent Director
--
--
Mr. Scott Garland
Mr. Scott Garland
Independent Director
Independent Director
--
--
Dr. Alan Sandler, M.D.
Dr. Alan Sandler, M.D.
Director
Director
--
--
Mr. Chris H. Takimoto, M.D., Ph.D.
Mr. Chris H. Takimoto, M.D., Ph.D.
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Jason Lettmann
Mr. Jason Lettmann
Chief Executive Officer, Director
Chief Executive Officer, Director
215.12K
+75.05%
Dr. Corey S. Goodman
Dr. Corey S. Goodman
Executive Chairman of the Board
Executive Chairman of the Board
167.37K
--
Mr. Harish Shantharam
Mr. Harish Shantharam
Chief Financial Officer
Chief Financial Officer
75.00K
--
Ms. Shelly Pinto
Ms. Shelly Pinto
Senior Vice President - Finance, Chief Accounting Officer
Senior Vice President - Finance, Chief Accounting Officer
39.07K
-1.54%
Ms. Rekha Hemrajani
Ms. Rekha Hemrajani
Independent Director
Independent Director
33.00K
+1000.00%
Dr. Daniel J. Curran, M.D.
Dr. Daniel J. Curran, M.D.
Independent Director
Independent Director
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Sun, Nov 16
Updated: Sun, Nov 16
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
VenBio Partners LLC
17.89%
HBM Partners AG
8.30%
Redmile Group, LLC
6.15%
Millennium Management LLC
5.88%
Lightstone Ventures, L.P.
5.44%
Other
56.34%
Shareholders
Shareholders
Proportion
VenBio Partners LLC
17.89%
HBM Partners AG
8.30%
Redmile Group, LLC
6.15%
Millennium Management LLC
5.88%
Lightstone Ventures, L.P.
5.44%
Other
56.34%
Shareholder Types
Shareholders
Proportion
Investment Advisor
18.64%
Private Equity
17.89%
Investment Advisor/Hedge Fund
12.37%
Hedge Fund
8.87%
Venture Capital
5.49%
Individual Investor
2.71%
Research Firm
2.50%
Bank and Trust
0.22%
Family Office
0.21%
Other
31.09%
Institutional Shareholding
Updated: Mon, Dec 8
Updated: Mon, Dec 8
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
244
35.78M
101.35%
+569.53K
2025Q3
254
35.25M
103.07%
-1.39M
2025Q2
258
36.65M
111.98%
-5.99M
2025Q1
265
42.61M
125.08%
-24.17M
2024Q4
271
47.78M
121.67%
+1.27M
2024Q3
264
48.70M
128.25%
-8.77M
2024Q2
268
51.75M
106.11%
+2.76M
2024Q1
264
49.00M
111.01%
-6.68M
2023Q4
265
50.25M
95.90%
+7.15M
2023Q3
279
38.17M
110.27%
-939.49K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
VenBio Partners LLC
9.70M
18.11%
--
--
Jun 30, 2025
HBM Partners AG
4.50M
8.4%
+1.07M
+31.31%
Mar 31, 2025
Redmile Group, LLC
3.39M
6.33%
-249.38K
-6.85%
Jun 30, 2025
Millennium Management LLC
492.61K
0.92%
-451.47K
-47.82%
Jun 30, 2025
Lightstone Ventures, L.P.
2.95M
5.51%
--
--
Mar 31, 2025
Almitas Capital LLC
2.54M
4.74%
+1.19M
+87.59%
Jun 30, 2025
The Vanguard Group, Inc.
1.60M
2.99%
-237.12K
-12.90%
Jun 30, 2025
Two Sigma Investments, LP
1.18M
2.21%
-42.42K
-3.47%
Jun 30, 2025
Acadian Asset Management LLC
1.27M
2.37%
-28.33K
-2.19%
Jun 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
Global X Russell 2000 Covered Call ETF
0%
Fidelity Fundamental Large Cap Growth ETF
0%
Goldman Sachs Innovate Equity ETF
0%
Global X Russell 2000 ETF
0%
Dimensional US Core Equity 1 ETF
0%
DFA Dimensional US Core Equity Market ETF
0%
Avantis US Equity ETF
0%
Avantis US Small Cap Equity ETF
0%
Invesco Nasdaq Biotechnology ETF
0%
Fidelity Fundamental Small-Mid Cap ETF
0%
View more
Global X Russell 2000 Covered Call ETF
Proportion0%
Fidelity Fundamental Large Cap Growth ETF
Proportion0%
Goldman Sachs Innovate Equity ETF
Proportion0%
Global X Russell 2000 ETF
Proportion0%
Dimensional US Core Equity 1 ETF
Proportion0%
DFA Dimensional US Core Equity Market ETF
Proportion0%
Avantis US Equity ETF
Proportion0%
Avantis US Small Cap Equity ETF
Proportion0%
Invesco Nasdaq Biotechnology ETF
Proportion0%
Fidelity Fundamental Small-Mid Cap ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of ALX Oncology Holdings Inc?
The top five shareholders of ALX Oncology Holdings Inc are:
VenBio Partners LLC holds 9.70M shares, accounting for 18.11% of the total shares.
HBM Partners AG holds 4.50M shares, accounting for 8.40% of the total shares.
Redmile Group, LLC holds 3.39M shares, accounting for 6.33% of the total shares.
Millennium Management LLC holds 492.61K shares, accounting for 0.92% of the total shares.
Lightstone Ventures, L.P. holds 2.95M shares, accounting for 5.51% of the total shares.
VenBio Partners LLC holds 9.70M shares, accounting for 18.11% of the total shares.
HBM Partners AG holds 4.50M shares, accounting for 8.40% of the total shares.
Redmile Group, LLC holds 3.39M shares, accounting for 6.33% of the total shares.
Millennium Management LLC holds 492.61K shares, accounting for 0.92% of the total shares.
Lightstone Ventures, L.P. holds 2.95M shares, accounting for 5.51% of the total shares.
What are the top three shareholder types of ALX Oncology Holdings Inc?
The top three shareholder types of ALX Oncology Holdings Inc are:
VenBio Partners LLC
HBM Partners AG
Redmile Group, LLC
VenBio Partners LLC
HBM Partners AG
Redmile Group, LLC
How many institutions hold shares of ALX Oncology Holdings Inc (ALXO)?
As of 2025Q4, 244 institutions hold shares of ALX Oncology Holdings Inc, with a combined market value of approximately 35.78M, accounting for 101.35% of the total shares. Compared to 2025Q3, institutional shareholding has increased by -1.73%.
What is the biggest source of revenue for ALX Oncology Holdings Inc?
In --, the -- business generated the highest revenue for ALX Oncology Holdings Inc, amounting to -- and accounting for --% of total revenue.
